BDKRB1 Antikörper (3rd Intracellular Loop, C250S)

Produktnummer ABIN7886088

Der Kaninchen Polyklonal anti-BDKRB1 Antikörper wird verwendet zum Nachweis von BDKRB1 in Proben von Ratte. Er wurde validiert für WB, IF, IHC und IC.

Kurzübersicht für BDKRB1 Antikörper (3rd Intracellular Loop, C250S) (ABIN7886088)

Target: BDKRB1 (Bradykinin Receptor B1 (BDKRB1))

Reaktivität: Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BDKRB1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (IHC), Immunochromatography (IC)

Güteklasse: KO Validated

Produktdetails anti-BDKRB1 Antikörper

Bindungsspezifität: 3rd Intracellular Loop, AA 243-257, C250S

Verwendungszweck: A Rabbit Polyclonal Antibody to B1 Bradykinin Receptor

Kreuzreaktivität: Maus, Ratte

Kreuzreaktivität (Details): Might not recognize the human epitope.

Homologie: Mouse - 13,15 amino acid residues identical

Produktmerkmale: Anti-B1 Bradykinin Receptor (BDKRB1) Antibody (ABIN7042967, ABIN7043940 and ABIN7043941) is a highly specific antibody directed against an epitope of the rat protein. The antibody can be used in western blot, immunohistochemistry, and immunocytochemistry applications. It has been designed to recognize B1R from rat and mouse samples. The antibody may not recognize the receptor from human samples.

Aufreinigung: Affinity purified on immobilized antigen.

Immunogen: (C)KEAS RTR*SG GPKGS K, corresponding to amino acid residues 243-257 of rat B1R with replacement of cysteine 250 (C250) with serine (*S)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

WB: 1:200

FC: The optimal concentration should be determined by the user

ICC: The optimal concentration should be determined by the user

IHC: 1:50

IP: The optimal concentration should be determined by the user

Kommentare:

Cited Application: IHC

Negative Control: (ABIN7234868)

Blocking Peptide: (ABIN7234868)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Konzentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Details zu BDKRB1

Target: BDKRB1 (Bradykinin Receptor B1 (BDKRB1))

Andere Bezeichnung: BDKRB1

Hintergrund:

Synonyms: B1R, BKR1, B1BKR, BKRB1, Kinin B1, BRADYB1

Description: Kinins are small peptides rapidly produced following tissue injury that serve as important modulators of inflammation and pain. In the periphery, the actions of kinins include vasodilatation, increased vascular permeability, stimulation of immune cells, and induction of pain. Kinins in the central nervous system (CNS) appear to initiate a similar cascade of events leading to neural tissue damage as well as long lasting disturbances affecting blood-brain barrier function.1Kinins such as Bradykinin (BK), Lys-BK, desArg9-BK, and Lys-desArg9-BK exert their action via two distinct receptors: the B1 Bradykinin receptor (BKRB1) and the B2 Bradykinin receptor (BKRB2). The desArg9-BK and Lys-desArg9-BK peptides activate BKRB1 while BK and Lys-BK operate by activating BKRB2.2 Both BKRB1 and BKRB2 are members of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily and share a common structure of seven putative transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxyl terminus.Expression of BKRB1is inducible upon various types of tissue injury and by inflammatory mediators such as bacterial lipopolysaccharide (LPS) and cytokines. BKRB1 was long considered not to be expressed in healthy tissues. However, recent work has demonstrated a low level of expression of BKRB1 in the CNS of rodent and primates. In contrast, BKRB2 is constitutively expressed on various cell types.3 BKRB1 represents a potential therapeutic target for treatment of inflammatory disorders and cardiovascular diseases.

Gen-ID: 81509

NCBI Accession: NM_000710

UniProt: P97583

Pathways: ACE Inhibitor Pathway